Journal of Clinical Endocrinology & Metabolism, Vol 65, 954-961, Copyright © 1987 by Endocrine Society

ARTICLES

Circulating immunoreactive inhibin levels during the normal human menstrual cycle

RI McLachlan, DM Robertson, DL Healy, HG Burger and DM de Kretser
Medical Research Centre, Prince Henry's Hospital, Melbourne, Australia.

Serum inhibin concentrations were measured daily by RIA in six normal women throughout one menstrual cycle. The RIA was specific for inhibin, and inhibin subunits and related proteins cross-reacted minimally in it. In the early to midfollicular phase, inhibin levels changed little, while in the late follicular phase, inhibin levels rose, in parallel with estradiol (r = 0.43; P less than 0.05; n = 22), to a peak level of 714 (407-1267) U/L (geometric mean +/- 67% confidence limits) coincident with the midcycle LH and FSH surges. An inverse relationship was found between serum inhibin and FSH during the mid- to late follicular phase (r = 0.42; P less than 0.01; n = 45). Inhibin levels rose further during the luteal phase to a peak level of 1490 (1086- 2028) U/L 7-8 days after the LH surge, and they correlated positively with serum progesterone (r = 0.76; P less than 0.001; n = 49) and inversely with serum FSH (r = 0.43; P less than 0.01; n = 49) throughout the luteal phase. We conclude that 1) circulating inhibin is detectable throughout the normal menstrual cycle; 2) in the late follicular phase, inhibin levels rise in parallel with estradiol, consistent with the concept that both are products of the maturing follicle; 3) in the luteal phase, the profile of inhibin suggests that it is a secretory product of the corpus luteum; and 4) the inverse relationship between inhibin and FSH in the follicular phase is consistent with the inhibin hypothesis, while at midcycle there is loss of the inhibitory effect of inhibin on FSH secretion. The inverse relationship between FSH and inhibin during the luteal phase suggests a hitherto unsuspected role for inhibin in the feedback regulation of FSH secretion.

This article has been cited by other articles:

				T. A. Lovick Plasticity of GABAA receptor subunit expression during the oestrous cycle of the rat: implications for premenstrual syndrome in women Exp Physiol, July 1, 2006; 91(4): 655 - 660. [Abstract] [Full Text] [PDF]

				C. Treetampinich, A. E. O'Connor, V. MacLachlan, N. P. Groome, and D. M. de Kretser Maternal serum inhibin A concentrations in early pregnancy after IVF and embryo transfer reflect the corpus luteum contribution and pregnancy outcome Hum. Reprod., September 1, 2000; 15(9): 2028 - 2032. [Abstract] [Full Text] [PDF]

				W G McCluggage Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms J. Clin. Pathol., May 1, 2000; 53(5): 327 - 334. [Abstract] [Full Text] [PDF]

				Z. Blumenfeld, I. Avivi, M. Ritter, and J. M. Rowe Preservation of Fertility and Ovarian Function and Minimizing Chemotherapy-Induced Gonadotoxicity in Young Women Reproductive Sciences, September 1, 1999; 6(5): 229 - 239. [Abstract] [PDF]

				H. M. Fraser, N. P. Groome, and A. S. McNeilly Follicle-Stimulating Hormone-Inhibin B Interactions during the Follicular Phase of the Primate Menstrual Cycle Revealed by Gonadotropin-Releasing Hormone Antagonist and Antiestrogen Treatment J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1365 - 1369. [Abstract] [Full Text]

				J. C. Prior Perimenopause: The Complex Endocrinology of the Menopausal Transition Endocr. Rev., August 1, 1998; 19(4): 397 - 428. [Abstract] [Full Text] [PDF]

				F. J. Hayes, J. E. Hall, P. A. Boepple, and W. F. Crowley Jr. Differential Control of Gonadotropin Secretion in the Human: Endocrine Role of Inhibin J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1835 - 1841. [Full Text]

				N. Zarghami, L. Grass, E. R. Sauter, and E. P. Diamandis Prostate-specific antigen in serum during the menstrual cycle Clin. Chem., October 1, 1997; 43(10): 1862 - 1867. [Abstract] [Full Text] [PDF]

				E. M. Wallace, N. P. Groome, S. C. Riley, A. C. Parker, and F. C. W. Wu Effects of Chemotherapy-Induced Testicular Damage on Inhibin, Gonadotropin, and Testosterone Secretion: A Prospective Longitudinal Study J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3111 - 3115. [Abstract] [Full Text] [PDF]

				C. K. Welt, K. A. Martin, A. E. Taylor, G. M. Lambert-Messerlian, W. F. Crowley Jr., J. A. Smith, D. A. Schoenfeld, and J. E. Hall Frequency Modulation of Follicle-Stimulating Hormone (FSH) during the Luteal-Follicular Transition: Evidence for FSH Control of Inhibin B in Normal Women J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2645 - 2652. [Abstract] [Full Text] [PDF]

				P. Pigny, R. Desailloud, C. Cortet-Rudelli, A. Duhamel, D. Deroubaix-Allard, A. Racadot, and D. Dewailly Serum {alpha}-Inhibin Levels in Polycystic Ovary Syndrome: Relationship to the Serum Androstenedione Level J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1939 - 1943. [Abstract] [Full Text] [PDF]

				D. L. Healy, H. G. Burger, P. Mamers, T. Jobling, M. Bangah, M. Quinn, P. Grant, A. J. Day, R. Rome, and J. J. Campbell Elevated Serum Inhibin Concentrations in Postmenopausal Women with Ovarian Tumors N. Engl. J. Med., November 18, 1993; 329(21): 1539 - 1542. [Abstract] [Full Text]